Partner Content - Pharmaceutical Technology

Managing gestational diabetes patients with an app: The midwife’s story

Fi Forrest — Wed, 03 Jan 2024 16:21:06 +0000

Paula Bandera, diabetes specialist midwife at Royal Surrey County Hospital, explains how using an app has revolutionised maternity care.

Expert analysis: the latest in HIV research and clinical trials

Fi Forrest — Wed, 03 Jan 2024 15:18:43 +0000

A new report from Novotech delves into the multifaceted landscape of HIV, focusing on its impact, treatment, and global initiatives.

EC grants approval for Kite’s cell therapy to treat follicular lymphoma

Vishnu Priyan — Wed, 29 Jun 2022 11:08:17 +0000

The EC has granted marketing authorization for Kite’s CAR T-cell therapy, Yescarta, to treat relapsed or refractory follicular lymphoma.

Avista and Roche to develop gene therapy vectors for eyes

Vishnu Priyan — Wed, 20 Jul 2022 13:22:26 +0000

Avista Therapeutics has entered a collaboration with Roche for developing new AAV gene therapy vectors for eyes.

Sangamo’s cell therapy receives EC orphan medicinal product designation

Hasini Devarasetti — Fri, 22 Jul 2022 14:04:52 +0000

Sangamo has received OMPD from the EC for its Investigational autologous CAR-Treg cell therapy, TX200, for solid organ transplantation.

GenScript and ACT partner to develop new CAR-T cell therapies

Vishnu Priyan — Wed, 13 Jul 2022 09:56:45 +0000

GenScript ProBio has signed a strategic collaboration MoU with ACT Therapeutics to develop a CAR-T cell therapy platform.

Vertex signs agreement to acquire ViaCyte for $320m

Vishnu Priyan — Tue, 12 Jul 2022 10:38:18 +0000

Vertex Pharmaceuticals has signed a definitive agreement for the acquisition of ViaCyte in a deal totalling $320m in cash.

Moderna to establish mRNA vaccine manufacturing centre in UK

Vishnu Priyan — Wed, 22 Jun 2022 09:56:20 +0000

Moderna has entered an agreement in principle with the UK government to set up a new mRNA vaccine manufacturing facility in the country.

What factors are driving life sciences FDI in 2022?

Julian Turner — Thu, 28 Jul 2022 09:11:36 +0000

Investment Monitor explores top drivers for greenfield FDI in the life sciences, including examples from Charleston, South Carolina.

The rise of eConsent adoption: Why now is the time to leave paper-based consent behind

Miranda McLaren — Fri, 29 Jul 2022 09:10:56 +0000

Clinical Trials Arena speaks to Suvoda’s Andrés Escallón on the advantages and barriers to eConsent adoption.

How autoinjector devices breathe new life into injectable medicines

miguelroca — Wed, 08 Dec 2021 11:00:24 +0000

The concept of modularity has variously been applied to myriad fields including evolutionary biology, psychology, industrial design and architecture, manufacturing, engineering, computer science, and far more besides. Clarifying what it means is therefore not straightforward due to the broad, abstract nature by which modularity can be perceived through distinct disciplinary lenses.

Solid Biosciences partners with Phlox for cardiac disease therapies

Hasini Devarasetti — Thu, 12 Jan 2023 14:52:34 +0000

Solid Biosciences has entered a strategic research collaboration with Phlox to develop new therapies for rare cardiac diseases.

Quality by design with a focus on biosimilars

Nat Schaefer — Fri, 28 Oct 2022 20:49:00 +0000

Fully integrated gas chromatography with PerkinElmer’s GC 2400

Nat Schaefer — Thu, 21 Jul 2022 10:42:00 +0000

CARsgen and Huadong Medicine to commercialise CT053 in mainland China

Hasini Devarasetti — Tue, 17 Jan 2023 07:05:34 +0000

CARsgen Therapeutics has announced a collaboration with Huadong Medicine to commercialise CT053 in mainland China.

Hospital Universitario and Josep Carreras develop cell therapy for leukaemia

Srivani Venna — Tue, 17 Jan 2023 15:52:54 +0000

Hospital Universitario 12 de Octubre and the Josep Carreras Leukaemia Research Institute have developed a cell therapy based on leukaemia.

Bluebird bio’s gene therapy Zynteglo could have high price tag defense in beta thalassemia

Adam Zamecnik — Mon, 25 Apr 2022 08:00:00 +0000

A $1 million price point is not out of question for bluebird bio’s beta thalassemia therapy if long-term benefits are substantiated.

Overcoming challenges with scalability in biopharma manufacturing

Alexander Love — Fri, 20 Jan 2023 09:01:18 +0000

Production of monoclonal antibodies (mAbs) therapies has traditionally been expensive and complicated. We speak to Dr Hani El-Sabbahy from 3M to understand more about overcoming problems with scalability and the reliability of clarification solutions.

Moderna takes aim at global expansion plans with manufacturing ramp-up

Akosua Mireku — Fri, 20 Jan 2023 16:33:34 +0000

At the WEF 2023, Moderna’s CEO envisioned plans to have an mRNA manufacturing facility on every continent to support post-pandemic growth.

Cyagen and Neurophth partner to develop gene therapy vectors

Vishnu Priyan — Tue, 08 Nov 2022 14:57:12 +0000

Cyagen and Neurophth Therapeutics have partnered to develop AAV gene therapy vectors for specific kinds of genetic ophthalmic ailments.